Petros Grivas/fredhutch.org
May 13, 2025, 02:24
Petros Grivas: No role of anti-PD(L)1 rechallenge in RCC
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared a post on X:
“Great talk by my colleague Scott Tykodi on RCC! Adjuvant pembro prolongs OS; 1L Ipi/nivo durable benefit in some patients with 99-month median follow up; no role of anti-PD(L)1 rechallenge based on Contact03 and TiNivo2 trials.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 24, 2025, 01:32
Aug 23, 2025, 22:57
Aug 23, 2025, 22:35
Aug 23, 2025, 22:10
Aug 23, 2025, 21:42
Aug 23, 2025, 21:31
Aug 23, 2025, 20:55
Aug 23, 2025, 20:22